Shots:

• The BREEZE study evaluates Tyvaso DPI vs nebulized Tyvaso in 51 patients with PAH who were transitioned from Tyvaso to Tyvaso DPI at a corresponding treprostinil dose
• The results demonstrated safety and tolerance with improvements in 6MWD compared to baseline- improvements in overall satisfaction- PAH Impact & PROs. Additionally- 96% completed 3wks. treatment phase & 2 patients discontinued due to treatment-related AEs- no study drug-related serious AEs were observed
• Tyvaso DPI is a drug-device combination therapy that contains a dry powder formulation of Tyvaso inhalation solution. Tyvaso DPI is currently under FDA’s review with an anticipated PDUFA date in Oct’21

Ref: United Therapeutics | Image: United Therapeutics